Oxford, UK, 24 July 2014 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that the United States patent for its biomarker platform CancerNav® has been issued. CancerNav® provides a powerful approach to discovering biomarkers that have the potential to predict responding and non-responding patients to a cancer drug. The platform is widely applicable to diverse cancer drugs and OCB has deployed it to successfully identify predictive biomarkers that can be developed as companion diagnostics for a variety of cancer drugs.
Nick La Thangue, CSO of Oxford Cancer Biomarkers, commented: “The issue of the United States patent is a major step forward in strengthening OCB’s position in biomarker discovery for personalised cancer medicine. It is an important milestone in attracting new partners to work with us.”
About Oxford Cancer Biomarkers
Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Its major investor is Quintiles with whom it also has a strategic relationship in the biomarker space.
For more information, please visit www.oxfordcancerbiomarkers.com or contact Nick La Thangue, CSO, on +44 1865 784743